LEADER 04411nam 2200529 450 001 9910137119603321 005 20230807212006.0 010 $a0-323-40107-4 035 $a(CKB)3710000000776361 035 $a(EBL)4620987 035 $a(OCoLC)956278034 035 $a(MiAaPQ)EBC4620987 035 $a(EXLCZ)993710000000776361 100 $a20160901h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aCancer screening and genetics /$fChristopher L. Wolfgang, MD, PhD 210 1$aPhiladelphia, Pennsylvania :$cElsevier,$d2015. 210 4$dİ2015 215 $a1 online resource (244 p.) 225 1 $aSurgical Clinics of North America,$x0039-6109 ;$vVolume 95, Number 5 300 $a"October 2015." 311 $a0-323-40106-6 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover image; Title page; Table of Contents; Copyright; Contributors; Consulting Editor; Editor; Authors; Forthcoming Issues; Forthcoming Issues; Recent Issues; Foreword: Cancer Screening and Genomics; Preface; Background; Cancer Genetics and Implications for Clinical Management; Key points; Introduction; Understanding the cancer genome landscape and translating advances for therapeutic gain; Driver versus passenger mutations; Mutational signatures in cancer; Rationale of genotype-guided medicine; Managing tumor heterogeneity and resistance to targeted therapy 327 $aAdvancing molecular phenotype-guided therapy in pancreatic cancerIndividualized therapy initiatives; Inherited susceptibility of cancer in the era of next-generation sequencing; Exceptional responders; Summary; The Triple-Code Model for Pancreatic Cancer; Key points; Cross talk between genetics and epigenetics as a promising paradigm in pancreatology; Mechanistic basis of epigenetics: the nucleosome; Marking the genome by methylation; Epigenetic regulation by noncoding RNAs; Shaping gene expression through nuclear architecture 327 $aEpigenetics opens a new era for pancreatic cancer markers and novel therapeutic modalitiesSummary; Principles of Cancer Screening; Key points; Introduction; Performance characteristics of screening tests; Measures of screening benefit; Common biases in assessing the benefits of screening; Harms of screening; Cost-effectiveness and targeted screening; Current recommended cancer screening tests in North America; Screening and Early Detection: Specific Diseases; Lung Cancer Screening; Key points; Introduction; Risks and harms of lung cancer screening; Practice of lung cancer screening; Summary 327 $aColorectal Cancer ScreeningKey points; Introduction: extent of the disease; Screening techniques and options; Clinical outcomes; Complications and concerns; Summary; Breast Cancer Screening; Key points; Introduction; Screening techniques and options; Personalized breast cancer screening; Complications and concerns; Summary; Screening for Viral Hepatitis and Hepatocellular Cancer; Key points; Screening for hepatitis B virus infection; Screening for hepatitis C virus infection; Diagnosing other viral hepatitides; Screening for hepatocellular carcinoma 327 $aWhen to obtain a liver biopsy to diagnose hepatocellular carcinomaProstate Cancer Screening and the Associated Controversy; Key points; Introduction; Screening techniques and options; Clinical outcomes; Complications and concerns; Summary; Screening for Pancreatic Cancer; Key points; Introduction; How early does pancreatic cancer have to be detected for cure?; Target lesions; Who is at risk of developing pancreatic cancer? Who should be screened?; How should suspected lesions be managed?; Screening and Early Detection of Gastric Cancer; Key points 327 $aGastric cancer epidemiology: mortality, incidence between east and west 410 0$aSurgical clinics of North America ;$vVolume 95, Number 5. 606 $aCancer$xGenetic aspects 606 $aCancer$xEarly detection 615 0$aCancer$xGenetic aspects. 615 0$aCancer$xEarly detection. 676 $a616.994042 700 $aWolfgang$b Christopher L.$01376864 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910137119603321 996 $aCancer screening and genetics$93413105 997 $aUNINA